Methods of producing an IL-1 RAP antibodies
AssigneeCantargia AB
InventorsHelena Ågerstam, Thoas Fioretos, Marcus Järås, Cecilia Ann-Christin Malmborg Hager, Kjell Sjöström, Agneta Svedberg, Karin Von Wachenfeldt
Life of this patent
Estimating the term…
Abstract
The present invention provides an antibody or an antigen-binding fragment thereof with binding specificity for human interleukin-1 receptor accessory protein (IL1RAP) wherein the antibody or antigen-binding fragment is capable of inhibiting the binding of antibody ‘CAN04’ to human IL1RAP. The invention further provides the use of such antibodies or an antigen-binding fragments in the treatment and/or diagnosis of IL-1 associated diseases and conditions, including cancers such as acute myeloid leukemia and melanoma.
Claims20
A method for producing an antibody or antigen-binding fragment, the method comprising culturing a host cell comprising a nucleic acid molecule encoding an antibody or antigen-binding fragment comprising:
- a. A heavy chain variable region (VH) comprising (i) heavy chain CDR1 comprising:
- GYAFTSS (amino acids 26-32 of SEQ ID NO:9);
- (ii) Heavy chain CDR2 comprising:
- YPGDGN (SEQ ID NO:
- 4);
- and (iii) Heavy chain CDR3 comprising:
- GYLDPMDY (SEQ ID NO:
- 5);
- and a light chain variable region (VL) comprising:
- (i) Light chain CDR 1 comprising:
- ASQGINNYLN (amino acids 25-34 of SEQ ID NO:16);
- (ii) Light chain CDR2 comprising:
- YTSGLHA (SEQ ID NO:
- 13);
- and (iii) Light chain CDR3 comprising:
- QQYSILPWT (SEQ ID NO:
- 14);
- b. A heavy chain variable region (VH) comprising (i) heavy chain CDR1 comprising GYAFTSS (amino acids 26-32 of SEQ ID NO:9);
- (ii) heavy chain CDR2 comprising YPGDGN (SEQ ID NO:
- 4);
- and (iii) heavy chain CDR3 comprising GYLDPMDY (SEQ ID NO:
- 5);
- and a light chain variable region (VL) comprising (i) light chain CDR 1 comprising SASQGINNYLN (SEQ ID NO:12);
- light chain CDR2 comprising YTSGLHA (SEQ ID NO:
- 13);
- and (iii) light chain CDR3 comprising QQYSILPWT (SEQ ID NO:
- 14);
- c. A heavy chain variable region (VH) comprising (i) heavy chain CDR1 comprising GYAFSSS (SEQ ID NO:3);
- (ii) heavy chain CDR2 comprising YPGDGN (SEQ ID NO:
- 4);
- and (iii) heavy chain CDR3 comprising GYLDPMDY (SEQ ID NO:
- 5);
- and a light chain variable region (VL) comprising (i) light chain CDR 1 comprising SASQGINNYLN (SEQ ID NO:12);
- light chain CDR2 comprising YTSGLHA (SEQ ID NO:
- 13);
- and (iii) light chain CDR3 comprising QQYSILPWT (SEQ ID NO:
- 14);
- d. A heavy chain variable region (VH) comprising (i) heavy chain CDR1 comprising GYAFSSS (SEQ ID NO:3);
- (ii) heavy chain CDR2 comprising YPGDGN (SEQ ID NO:
- 4);
- and (iii) heavy chain CDR3 comprising GYLDPMDY (SEQ ID NO:
- 5);
- and a light chain variable region (VL) comprising (i) light chain CDR 1 comprising ASQGINNYLN (amino acids 25-34 of SEQ ID NO:16);
- light chain CDR2 comprising YTSGLHA (SEQ ID NO:
- 13);
- and (iii) light chain CDR3 comprising QQYSILPWT (SEQ ID NO:
- 14);
- e. A heavy chain variable region (VH) comprising (i) heavy chain CDR1 comprising GYTFTSS (amino acids 26-32 of SEQ ID NO:10);
- (ii) heavy chain CDR2 comprising YPGDGQ (amino acids 52-57 of SEQ ID NO:10);
- and (iii) heavy chain CDR3 comprising GYLDPMDY (SEQ ID NO:
- 5);
- and a light chain variable region (VL) comprising (i) light chain CDR 1 comprising SASQGINNYLN (SEQ ID NO:12);
- light chain CDR2 comprising YTSGLHA (SEQ ID NO:
- 13);
- and (iii) light chain CDR3 comprising QQYSILPWT (SEQ ID NO:
- 14);
- or
- f. A heavy chain variable region (VH) comprising (i) heavy chain CDR1 comprising GYTFTSS (amino acids 26-32 of SEQ ID NO:10);
- (ii) heavy chain CDR2 comprising YPGDGQ (amino acids 52-57 of SEQ ID NO:10);
- and (iii) heavy chain CDR3 comprising GYLDPMDY (SEQ ID NO:
- 5);
- and a light chain variable region (VL) comprising (i) light chain CDR 1 comprising ASQGINNYLN (amino acids 25-34 of SEQ ID NO:16);
- light chain CDR2 comprising YTSGLHA (SEQ ID NO:
- 13);
- and (iii) light chain CDR3 comprising QQYSILPWT (SEQ ID NO:
- 14);
- under conditions that permit expression of the encoded antibody or antigen-binding fragment.
Dependencies are inferred from the claim text.